PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharma in a “Fireside Chat” at the Evercore ISI 4th Annual HealthCONx Conference.
CRANBURY, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharma in a “Fireside Chat” at the Evercore ISI 4th Annual HealthCONx Conference taking place November 30 – December 2, 2021. The company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
| Evercore ISI 4th Annual HealthCONx Conference | |
| Date: | Thursday, December 2, 2021 |
| Time: | 11:20 am ET |
| Format: | Fireside Chat |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contact
For Investors:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
